Cultivecs
Cultivecs Inc. is a company that develops and manufactures antibody drugs, aiming to contribute to society through the stable supply of high-quality, low-cost biopharmaceuticals using state-of-the-art technology. The company was established in 2016 and operates a GMP-compliant manufacturing facility in Niigata, Japan, with a focus on antibody drug development and manufacturing, including contract manufacturing services. Cultivecs is committed to providing efficient, high-quality biopharmaceuticals by utilizing advanced manufacturing techniques and maintaining close communication with clients.
Industries
Nr. of Employees
small (1-50)
Services
Manufacture of antibody active pharmaceutical ingredient (API) for preclinical, clinical, and commercial supply using GMP-compliant processes.
Production and handling of master and working cell banks to support biologics manufacturing and technology transfer.
Process evaluation and optimization to support transfer from development to GMP manufacturing, including upstream and downstream process studies.
In-process monitoring, release testing, stability testing, and analytical method development/validation for biopharmaceutical products.
QA functions including SOP/document control, change and deviation management, audits, training, and inspection support aligned with GMP requirements.
Coordination with partner organizations to provide services spanning cell line development, preclinical support, GMP manufacturing, and clinical supply.
Manufacture of antibody active pharmaceutical ingredient (API) for preclinical, clinical, and commercial supply using GMP-compliant processes.
Production and handling of master and working cell banks to support biologics manufacturing and technology transfer.
Process evaluation and optimization to support transfer from development to GMP manufacturing, including upstream and downstream process studies.
In-process monitoring, release testing, stability testing, and analytical method development/validation for biopharmaceutical products.
QA functions including SOP/document control, change and deviation management, audits, training, and inspection support aligned with GMP requirements.
Coordination with partner organizations to provide services spanning cell line development, preclinical support, GMP manufacturing, and clinical supply.
Expertise Areas
- Contract manufacturing (CMO) for antibody therapeutics
- GMP manufacturing for biologics
- Upstream mammalian cell culture at scale
- Downstream purification and process scale-up
Key Technologies
- Single-use bioreactors (200 L–2,000 L scale)
- Large-scale mammalian cell culture
- Downstream purification (chromatography-based workflows)
- Master/working cell bank production
News & Updates
Representative Director, President Takao Ota's appointment
On June 10, 2020, Takao Ota was appointed as the President of Cultivecs Inc.
Participation in research project by AMED
Cultivecs participated in a research project conducted by the Japan Agency for Medical Research and Development (AMED) in 2021.
Joining the Next-Generation Biopharmaceutical Manufacturing Technology Research Union
Cultivecs joined the research union on June 25, 2021, focusing on next-generation biopharmaceutical manufacturing technologies.
Compliance consultation window established
The company established a compliance consultation window on October 28, 2021.
Address publication of Niigata factory
The address of the Niigata factory was published on July 26, 2018.
Designation as a target project for Niigata City Industrial Promotion Subsidy
The Niigata City Industrial Promotion Subsidy program designated Cultivecs' project on August 23, 2018.
Representative Director, President Takao Ota's appointment
On June 10, 2020, Takao Ota was appointed as the President of Cultivecs Inc.
Participation in research project by AMED
Cultivecs participated in a research project conducted by the Japan Agency for Medical Research and Development (AMED) in 2021.
Joining the Next-Generation Biopharmaceutical Manufacturing Technology Research Union
Cultivecs joined the research union on June 25, 2021, focusing on next-generation biopharmaceutical manufacturing technologies.
Compliance consultation window established
The company established a compliance consultation window on October 28, 2021.
Address publication of Niigata factory
The address of the Niigata factory was published on July 26, 2018.
Designation as a target project for Niigata City Industrial Promotion Subsidy
The Niigata City Industrial Promotion Subsidy program designated Cultivecs' project on August 23, 2018.